Author:
Devineni Damayanthi,Curtin Christopher R.,Marbury Thomas C.,Smith William,Vaccaro Nicole,Wexler David,Vandebosch An,Rusch Sarah,Stieltjes Hans,Wajs Ewa
Subject
Pharmacology (medical),Pharmacology
Reference58 articles.
1. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030;Whiting;Diabetes Res Clin Pract,2011
2. Canagliflozin (Invokana™) Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdf. Accessed on July 24, 2014.
3. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin;Devineni;Diabetes Obes Metab,2012
4. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models;Liang;PLoS One,2012
5. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus;Nomura;J Med Chem,2010
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献